Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Taiho Pharmaceutical Announces Results of Randomized Phase II Clinical Trial with Novel Antitumor Agent TAS-102

July 22, 2011 By Bio-Medicine.Org

TOKYO, July 22, 2011 /PRNewswire/ — Taiho Pharmaceutical Co.,
Ltd. (HQ: Tokyo, President: Toru Usami) announced on July 22 the
results of a randomized, Phase II clinical trial for the novel oral
nucleoside antitumor agent TAS-102 under development by the company
for metastatic colorectal cancer, at the 9th Annual Meeting of the
Japanese Society of Medical Oncology held in Yokohama. (Abstract
no. 10428)

The trial was a randomized, double-blind, placebo-controlled
study with a primary outcome measure of overall survival involving
172 patients with refractory metastatic colorectal cancer who had
received standard chemotherapy at least two or more regimens
containing a fluoropyrimidine, irinotecan, and oxaliplatin. The
results indicated that the TAS-102 significantly improved overall
survival compared with the placebo (overall survival median: 9.0
months vs. 6.6 months) and significantly reduced the risk of
mortality (HR=0.56, p=0.0011). Also, no instances of
treatment-related mortality were reported. The most frequently
reported adverse drug reaction with a CTCAE grade 3 or higher was
neutropenia. Grade 3 or higher diarrhea, fatigue, nausea, and other
adverse reactions were no more than 10%.

In light of these results, Taiho Pharmaceutical will proceed
with global development of TAS-102 so that this drug can be offered
as soon as possible to metastatic colorectal cancer patients who
have exhausted proven treatment options and there remains a high
unmet medical need.

About TAS-102:

TAS-102 is a novel oral nucleoside antitumor agent with a novel
mechanism of action, composed of a mixture of Trifluorothymidine
(FTD), which demonstrates antitumor effects through incorporation
into DNA, and
5-chloro-6-(2-iminopyrrolidin-1-yl)-methyl-2,4(1H,3H)-pyrimidinedione
hydrochloride (TPI), which inhibits the degradation of FTD. Phase I
trials began in Japan in 2005, and the drug continues to be
developed as a treatment for colorectal cancer refra

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech